Agistin Biotech Profile
Key Indicators
- Authorised Capital ₹ 4.00 M
as on 16-11-2024
- Paid Up Capital ₹ 3.94 M
as on 16-11-2024
- Company Age 12 Year, 8 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 3.50 Cr
as on 16-11-2024
- Satisfied Charges ₹ 3.60 Cr
as on 16-11-2024
- Revenue -35.37%
(FY 2023)
- Profit 7.77%
(FY 2023)
- Ebitda -241.99%
(FY 2023)
- Net Worth 10.57%
(FY 2023)
- Total Assets 29.49%
(FY 2023)
About Agistin Biotech
The Company is engaged in the Agriculture Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 4.00 M and a paid-up capital of Rs 3.94 M.
The company currently has active open charges totaling ₹3.50 Cr. The company has closed loans amounting to ₹3.60 Cr, as per Ministry of Corporate Affairs (MCA) records.
Vasant Patel and Jitendra Patel serve as directors at the Company.
- CIN/LLPIN
U15122GJ2012PTC069786
- Company No.
069786
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
10 Apr 2012
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Ahmedabad, Gujarat, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Agistin Biotech Private Limited offer?
Agistin Biotech Private Limited offers a wide range of products and services, including Cereals & Food Grains, Basmati Rice, Food Grains, Rice, Seeds and Plant Saplings, Hybrid Seeds, Ayurvedic Powder and Medicinal Herbs, Herb Leaves, 1121 Basmati Rice, Green Millet.
Who are the key members and board of directors at Agistin Biotech?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Vasant Patel  | Director | 10-Apr-2012 | Current |
| Jitendra Patel | Director | 10-Apr-2012 | Current |
Financial Performance and Corporate Structure Insights of Agistin Biotech.
Agistin Biotech Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 35.37% decrease. The company also saw a slight improvement in profitability, with a 7.77% increase in profit. The company's net worth Soared by an impressive increase of 10.57%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Agistin Biotech?
In 2023, Agistin Biotech had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 18 Aug 2023 | ₹3.50 Cr | Open |
Others Creation Date: 28 Dec 2021 | ₹2.00 Cr | Satisfied |
Others Creation Date: 29 Jun 2016 | ₹4.12 M | Satisfied |
How Many Employees Work at Agistin Biotech?
Unlock and access historical data on people associated with Agistin Biotech, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Agistin Biotech, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Agistin Biotech's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
